Latest Articles

Publication Date
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
Endometriosis and long-term risk of venous thromboembolism: a Danish nationwide study.

Endometriosis affects ∼10% of women of reproductive age. Emerging evidence suggests a link between endometriosis and systemic inflammation, potentially increasing the risk of venous thromboembolism (VTE), yet data on the …

Published: Aug. 8, 2026, midnight
Endometrial cells with high ALDH activity contribute to uterine development and regeneration.

Adult stem cells are thought to drive the regenerative potential of the endometrium and contribute to the pathogenesis of endometriosis; however, their identity and defining features remain to be characterized. …

Published: Aug. 6, 2026, midnight
Endometriosis subtypes and risk of type 2 diabetes: the Advancing Research on Cardiovascular Health and Endometriosis Study (ARCHES) retrospective cohort study.

Endometriosis is a heterogeneous inflammatory condition that may influence long-term metabolic health. Prior studies have reported largely null associations with type 2 diabetes, potentially missing subtype-specific and subgroup heterogeneity. We …

Published: Aug. 6, 2026, midnight
Long-term clinical effectiveness of endovenous interventions for pelvic venous disorders.

Endovenous therapies are the current standard of care for the management of pelvic venous disorders (PeVD) secondary to pelvic venous insufficiency. We previously reported superior short-term results after iliac vein …

Published: Aug. 5, 2026, midnight
EGF as a non-invasive biomarker of endometriosis: a case control study.

Endometriosis is a chronic inflammatory condition that affects an estimated 1 in 10 women but is often mis- and underdiagnosed due to its non-specific symptoms and the lack of a …

Published: July 29, 2026, midnight
Exploring New Treatment Strategies for Endometriosis-Narrative Review.

The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …

Published: July 28, 2026, midnight
Beyond Antioxidant Activity, Towards Redox Modulation: N-Acetylcysteine (NAC) in Endometriosis and Uterine Leiomyomas.

Endometriosis and uterine leiomyomas are common chronic gynecologic diseases associated with immune dysregulation, inflammation and aberrant cellular proliferation, processes that contribute to increased oxidative stress. Current management relies largely on …

Published: July 27, 2026, midnight
Assisted Reproductive Technology in Breast and Gynecologic Malignancies: Cancer Risk, Fertility Preservation, and Post-Treatment Reproductive Outcomes.

Assisted reproductive technology (ART) is increasingly utilized worldwide, yet concerns remain regarding its potential association with breast and gynecological malignancies and the safety of fertility-preservation strategies in cancer survivors. Ovarian …

Published: July 24, 2026, midnight
The Therapeutic Role of Dienogest in Endometriosis-Associated Pain: From Basics to Clinics.

The most common symptom of endometriosis is pain. The pathogenesis of endometriosis-associated pain remains unclear. In this review, we illustrate the pathogenesis of endometriosis-associated pain and the mechanisms of dienogest …

Published: July 23, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!